エチオナミド

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

  H361：生殖能または胎児への悪影響のおそれの疑い

• 注意書き

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

エチオナミド 価格

MSDS Information

• 2-Ethylpyridine-4-carbothioamide

エチオナミド 化学特性,用途語,生産方法

• 外観

  うすい黄色～黄色～黄赤色粉末～結晶

• 解説

  エチオナミド，抗結核薬。抗結核菌作用はイソニアジドよりも弱いが、イソニアジド耐性菌に有効である。副作用としては食欲不振、悪心(おしん)、嘔吐(おうと)などの胃障害が主で、重大なものとして、劇症肝炎、急性肝炎など重篤な肝障害が現れることがある。1日0.3グラムから始めて漸増し、0.5～0.7グラムを1～3回に分服する。なお、坐薬(ざやく)もあったが、やはり副作用として胃障害がみられた。

• 効能

  抗結核薬

• 商品名

  ツベルミン (Meiji Seikaファルマ)

• 説明

  Ethionamide is an antimycobacterial compound that is active against M. tuberculosis (MICs = 0.3-1.25 μg/ml). It is activated via oxidation by flavin monooxygenase and inhibits the InhA enzyme involved in mycolic acid biosynthesis. Formulations containing ethionamide have been used in the second-line treatment of multi-drug resistant tuberculosis.

• 化学的特性

  Yellow Solid

• 使用

  Ethionamide is used in antimicrobials and in potency assay of test compounds on M. tuberculosis.

• 定義

  ChEBI: A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.

• 適応症

  Ethionamide (Trecator) is a derivative of isonicotinic acid and is chemically related to isoniazid. It is a secondary agent used in combination when primary agents are ineffective or contraindicated; it is a bacteriostatic antituberculosis agent. Its exact mechanism of action is unknown but is believed to involve inhibition of oxygen-dependent mycolic acid synthesis. It is thought that mutations in the region of the (inhA) gene that are involved in mycolic acid synthesis can cause both isoniazid and ethionamide resistance.

• 一般的な説明

  Yellow crystals or canary yellow powder with a faint to moderate sulfide odor.

• 空気と水の反応

  Insoluble in water.

• 反応プロフィール

  A thiocarbamate/amine. Thiocarbamates slowly decompose in aqueous solution to form carbon disulfide and methylamine or other amines. Such decompositions are accelerated by acids. Flammable gases are generated by the combination of thiocarbamates and dithiocarbamates with aldehydes, nitrides, and hydrides. Thiocarbamates and dithiocarbamates are incompatible with acids, peroxides, and acid halides.

• 火災危険

  Flash point data for Ethinamide are not available. Ethinamide is probably combustible.

• 作用機序

  Evidence has been presented suggesting that the mechanism of action of ethionamide is similar to that of INH. Similar to INH, ethionamide is considered to be a pro-drug, which is converted via oxidation by catalase-peroxidase to an active acylating agent, ethionamide sulfoxide, which in turn inactivates the inhA enoyl reductase enzyme. In the case of ethionamide, it has been proposed that the ethionamide sulfoxide acylates Cys-243 in inhA protein.

• 薬理学

  Ethionamide is well absorbed following oral administration. It is rapidly and widely distributed to all body tissues and fluids, including the cerebrospinal fluid. Metabolism of ethionamide is extensive, and several dihydropyridine metabolites are produced. Less than 1% of the drug is eliminated in the urine unchanged. GI disturbances, including nausea, vomiting, and intense gastric irritation, are frequent. In addition, ethionamide may cause a wide range of neurological side effects, such as confusion, peripheral neuropathy, psychosis, and seizures. Neurological effects can be minimized by pyridoxine supplementation. Other rare side effects include gynecomastia, impotence, postural hypotension, and menorrhagia.

• 臨床応用

  2-Ethylthioisonicotinamide (Trecator SC) occurs as a yellowcrystalline material that is sparingly soluble in water. Thisnicotinamide has weak bacteriostatic activity in vitro but, becauseof its lipid solubility, is effective in vivo. In contrast tothe isoniazid series, 2-substitution enhances activity in thethioisonicotinamide series.
  Ethionamide is rapidly and completely absorbed followingoral administration. It is widely distributed throughoutthe body and extensively metabolized to predominantly inactiveforms that are excreted in the urine. Less than 1% ofthe parent drug appears in the urine.Ethionamide is considered a secondary drug for the treatmentof tuberculosis. It is used in the treatment of isoniazidresistanttuberculosis or when the patient is intolerant toisoniazid and other drugs. Because of its low potency, thehighest tolerated dose of ethionamide is usually recommended.Gastrointestinal intolerance is the most commonside effect associated with its use. Visual disturbances andhepatotoxicity have also been reported.

• 代謝

  Ethionamide is orally active but is not well tolerated in a single large dose (>500 mg). The GI irritation can be reduced by administration with meals. Additional side effects may include central nervous system (CNS) effects, hepatitis, and hypersensitivities. Less than 1% of the drug is excreted in the free form, with the remainder of the drug appearing as one of six metabolites. Among the metabolites are ethionamide sulfoxide, 2-ethylisonicotinamide, and the N-methylated- 6-oxodihydropyridines.

• 純化方法

  It crystallises from EtOH as lemon yellow needles. The hydrochloride crystallises from EtOH (+ few drops of HCl) as orange yellow needles with m 212-214o. [Kutscherowa et al. J Gen Chem USSR (English transl) 29 915 1959, Beilstein 22 III/IV 737.] It causes peripheral and occular neuropathy and is carcinogenic and teratogenic.

エチオナミド 上流と下流の製品情報

エチオナミド 生産企業

Global(285)Suppliers

エチオナミド スペクトルデータ(IR1、MS)

536-33-4, エチオナミド キーワード